Who to call at Nimbus Therapeutics, and when
Fundz watches for the moments Nimbus Therapeutics starts buying, and tells you who to reach.
- An alert the day Nimbus Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nimbus Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nimbus Therapeutics. With Fundz connected, it knows.
LaunchNimbus Therapeutics Announces Positive Updated Data from Clinical Trial of HPK1 Inhibitor NDI-101150 for Advanced Solid Tumors
BostonBiotechnologyHealth CareTherapeuticsPharmaceuticalProduct Description
Nimbus Therapeutics presented new clinical and translational data from its Phase 1/2 trial of NDI-101150, a HPK1 inhibitor, at the SITC Annual Meeting, showcasing encouraging results for patients with advanced solid tumors.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nimbus Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Product Launch Insights
What this usually meansNimbus Therapeutics shipped something new. Fundz reads product launches, trademark filings and hiring together.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.